Cite
HARVARD Citation
Cohen, S. et al. (2019). Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. Lancet. pp. e23-e34. [Online].